Warburg Pincus Xi, LP

Warburg Pincus & Co. exits SHC entirely, selling 19,102,952 shares at $15.17 for $289,753,575.94, reducing stake to 0.

Warburg Pincus & Co. (Director) sold its entire position of 19,102,952 shares of Sotera Health Co (SHC) at $15.17 on 2026-05-13 for total proceeds of $289,753,575.94, leaving 0 shares post-transaction — a complete exit from the company. This sale occurred with SHC trading -23.1% below its 52-week high of $19.85, and the stock has declined -4.7% over the prior 30 days and -10.8% over the prior 90 days. Across Warburg Pincus & Co.'s cross-ticker sell history, the 90-day well-timed rate stands at 50.00%, and prior sells at SHC specifically showed mixed outcomes: the March 2026 sells produced a 30-day return of -2.0% and a 90-day return of +1.4%, while the December 2025 sells showed a 30-day return of +8.3% and a 90-day return of -3.9%. The complete liquidation of a 19.10M share position by a Director-level holder is a material ownership event regardless of prior timing patterns, and investors should note that SHC trades at a P/E of 37.24 against a market cap of $4.4B with quarterly net income of $26,589,000.

Warburg Pincus (Director) sells 15.00M SHC shares at $15.27; holdings drop 44.0% to 19.10M shares as stock falls -27.3% from 52-week high.

Warburg Pincus sold 15,000,000 shares of Sotera Health on 2026-03-06 at $15.27, reducing its stake by -44.0% from 34,102,952 to 19,102,952 shares, representing a $229,050,000.00 reduction in holdings. The stock has declined to $14.06, now -27.3% from its 52-week high of $19.35, with a -20.8% drop over 30 days and -16.8% over 90 days, suggesting the market has repriced the company post-transaction. At the same ticker, Warburg Pincus' prior four measurable sales showed mixed timing: 2 of 4 were well-timed at the 90-day mark (2025-11-10 sales both showed +7.9% at 30d and +13.4% at 90d, indicating the stock rose after those sales), while 2 of 4 were poorly timed (2025-12-03 sales both returned +8.3% at 30d but -3.9% at 90d). The current transaction's large scale and the stock's sharp subsequent decline warrant monitoring to assess whether this sale signals a change in confidence or market conditions at Sotera Health.

Warburg Pincus & Co. sold 18,000,000 shares of Sotera Health at $15.65, reducing holdings by -29.1%, raising $281.7M

Warburg Pincus & Co. executed a major capital reduction at Sotera Health, divesting 18,000,000 shares (-29.1% of pre-transaction holdings) for $281,718,000.00. The sale occurred at $15.65, trading 3.8% below the 52-week high of $16.90, near the upper end of the 52-week range. Across his open-market history, this insider's prior sales exhibited a 90-day well-timed rate of 100.00%, and at this specific ticker, 2 of 2 prior measurable 90-day outcomes from sales yielded declines (-13.7% in both cases). The company trades at a P/E of 81.25 on quarterly revenue of $311,312,000.00 and net income of $48,400,000.00, with modest annual growth of +4.9%. The execution of a large block sale by a significant shareholder represents a material portfolio action that may reflect capital deployment priorities rather than confidence in near-term equity appreciation at current valuation levels.

Warburg Pincus sells 12,000,000 SHC shares for $181.3M; holds 61.82M shares; 4 of 4 prior sells at this ticker fell 90-days later.

Warburg Pincus (Director) divested 12,000,000 shares of Sotera Health at $15.11 on 2025-09-05, reducing holdings from 73.82M to 61.82M shares (-16.3%). This sale is noteworthy given the insider's prior trading pattern at SHC: all 4 measurable historical sales (2024-09-06 and 2024-03-04) were followed by 90-day declines of -13.7% and -21.9% respectively, a 100% accuracy rate in preceding downturns. The current stock price of $15.81 sits just 4.6% above the transaction price and has rebounded 31.1% over 90 days from prior lows, meaning the timing utility of this sale cannot yet be assessed. At a P/E of 197.62 and net income of only $8.0M on revenue of $294.3M, the company carries an elevated valuation multiple relative to profitability, which may frame investor concerns about sustainability. The scale of this divestiture—a $181.3M transaction representing significant position reduction—and the director's demonstrated pattern of selling ahead of subsequent declines should prompt monitoring of the 90-day forward price action.

Warburg Pincus director sold 15,000,000 shares of SHC at $15.03 on 2024-09-06 for $225,450,000.00.

WARBURG PINCUS & CO. exited a substantial portion of its SHC position, selling 15,000,000 shares (16.9% of prior holdings) at $15.03, reducing its stake from 88,822,952 to 73,822,952 shares. The director's prior two sales at this ticker both delivered negative 90-day returns (-21.9%), establishing a pattern of well-timed exits at SHC. The stock has since rallied +38.5% over 90 days and now trades at $16.80, above the transaction price of $15.03. This large director sale, though historically aligned with the insider's timing accuracy at this specific ticker, occurred ahead of significant subsequent gains, contrasting with the favorable 90-day outcomes of the two prior SHC sales. Given the company's stretched P/E of 120.00 against modest revenue growth of +4.5% annually, the sale warrants investor attention to management's confidence signals and valuation sustainability.